Cargando…
A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245883/ https://www.ncbi.nlm.nih.gov/pubmed/32448257 http://dx.doi.org/10.1186/s12884-020-03008-5 |
_version_ | 1783537838236631040 |
---|---|
author | Anger, Holly A. Dabash, Rasha Hassanein, Nevine Darwish, Emad Ramadan, Mohamed Cherine Nawar, Medhat Charles, Dyanna Breebaart, Miral Winikoff, Beverly |
author_facet | Anger, Holly A. Dabash, Rasha Hassanein, Nevine Darwish, Emad Ramadan, Mohamed Cherine Nawar, Medhat Charles, Dyanna Breebaart, Miral Winikoff, Beverly |
author_sort | Anger, Holly A. |
collection | PubMed |
description | BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given the difficulty of routinely measuring blood loss for all deliveries, more operational models of secondary prevention are needed. METHODS: This cluster-randomized, non-inferiority trial included women giving birth with nurse-midwives at home or in Primary Health Units (PHUs) in rural Egypt. Two PPH management approaches were compared: 1) 600mcg oral misoprostol given to all women after delivery (i.e. primary prevention, current standard of care); 2) 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss estimated using an underpad (i.e. secondary prevention). The primary outcome was mean change in pre- and post-delivery hemoglobin. Secondary outcomes included hemoglobin ≥2 g/dL and other PPH interventions. RESULTS: Misoprostol was administered after delivery to 100% (1555/1555) and 10.7% (117/1099) of women in primary and secondary prevention clusters, respectively. The mean drop in pre- to post-delivery hemoglobin was 0.37 (SD: 0.91) and 0.45 (SD: 0.76) among women in primary and secondary prevention clusters, respectively (difference adjusted for clustering = 0.01, one-sided 95% CI: < 0.27, p = 0.535). There were no statistically significant differences in secondary outcomes, including hemoglobin drop ≥2 g/dL, PPH diagnosis, transfer to higher level, or other interventions. CONCLUSIONS: Misoprostol for secondary prevention of PPH is comparable to universal prophylaxis and can be implemented using local materials, such as underpads. TRIAL REGISTRATION: Clinicaltrials.gov NCT02226588, date of registration 27 August 2014. |
format | Online Article Text |
id | pubmed-7245883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72458832020-06-01 A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt Anger, Holly A. Dabash, Rasha Hassanein, Nevine Darwish, Emad Ramadan, Mohamed Cherine Nawar, Medhat Charles, Dyanna Breebaart, Miral Winikoff, Beverly BMC Pregnancy Childbirth Research Article BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given the difficulty of routinely measuring blood loss for all deliveries, more operational models of secondary prevention are needed. METHODS: This cluster-randomized, non-inferiority trial included women giving birth with nurse-midwives at home or in Primary Health Units (PHUs) in rural Egypt. Two PPH management approaches were compared: 1) 600mcg oral misoprostol given to all women after delivery (i.e. primary prevention, current standard of care); 2) 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss estimated using an underpad (i.e. secondary prevention). The primary outcome was mean change in pre- and post-delivery hemoglobin. Secondary outcomes included hemoglobin ≥2 g/dL and other PPH interventions. RESULTS: Misoprostol was administered after delivery to 100% (1555/1555) and 10.7% (117/1099) of women in primary and secondary prevention clusters, respectively. The mean drop in pre- to post-delivery hemoglobin was 0.37 (SD: 0.91) and 0.45 (SD: 0.76) among women in primary and secondary prevention clusters, respectively (difference adjusted for clustering = 0.01, one-sided 95% CI: < 0.27, p = 0.535). There were no statistically significant differences in secondary outcomes, including hemoglobin drop ≥2 g/dL, PPH diagnosis, transfer to higher level, or other interventions. CONCLUSIONS: Misoprostol for secondary prevention of PPH is comparable to universal prophylaxis and can be implemented using local materials, such as underpads. TRIAL REGISTRATION: Clinicaltrials.gov NCT02226588, date of registration 27 August 2014. BioMed Central 2020-05-24 /pmc/articles/PMC7245883/ /pubmed/32448257 http://dx.doi.org/10.1186/s12884-020-03008-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Anger, Holly A. Dabash, Rasha Hassanein, Nevine Darwish, Emad Ramadan, Mohamed Cherine Nawar, Medhat Charles, Dyanna Breebaart, Miral Winikoff, Beverly A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title | A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title_full | A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title_fullStr | A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title_full_unstemmed | A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title_short | A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt |
title_sort | cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in egypt |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245883/ https://www.ncbi.nlm.nih.gov/pubmed/32448257 http://dx.doi.org/10.1186/s12884-020-03008-5 |
work_keys_str_mv | AT angerhollya aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT dabashrasha aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT hassaneinnevine aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT darwishemad aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT ramadanmohamedcherine aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT nawarmedhat aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT charlesdyanna aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT breebaartmiral aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT winikoffbeverly aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT angerhollya clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT dabashrasha clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT hassaneinnevine clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT darwishemad clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT ramadanmohamedcherine clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT nawarmedhat clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT charlesdyanna clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT breebaartmiral clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt AT winikoffbeverly clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt |